Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety and Tolerability of Posdinemab in Healthy Chinese Participants
NCT05407818Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2022
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of posidinemab in Alzheimer's disease (AD), sponsored by Janssen Pharmaceutical. Primary endpoint: Serum Concentrations of JNJ-63733657. Started Jun 2022; status: completed.
02
Drugs
posidinemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05407818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05407818.